Exploring QSAR for CYP11B2 binding affinity and CYP11B2/CYP11B1 selectivity of diverse functional compounds using GFA and G/PLS techniques

References

• Benjamin B, Karsten D, Rita B. Conferring aldosterone synthesis to human CYP11B1 by replacing key amino acid residues with CYP11B2-specific ones. Eur J Biochem 1998;252:458–66.
   PubMedGoogle Scholar
• Kawamoto T, Mitsuuchi Y, Toda K, Yokoyama Y, Miyakara K, Miura S, et al. Role of steroid 11beta-hydroxylase and steroid 18-hydroxylase in the biosynthesis of glucocorticoids and mineralocorticoids in humans. Proc Natl Acad Sci USA 1992;89:1458–62.
   PubMed Web of Science ®Google Scholar
• Takeda Y. Vascular synthesis of aldosterone: role in hypertension. Mol Cell Endocrinol 2004;217:75–9.
   PubMed Web of Science ®Google Scholar
• Davies E, MacKenzie SM. Extra-adrenal production of corticosteroids. Clin Exp Pharmacol Physiol 2003;30:437–45.
   PubMed Web of Science ®Google Scholar
• Brilla CG. Renin-angiotensin-aldosterone system and myocardial fibrosis. Cardiol Vasc Res 2000;47:1–3.
   PubMed Web of Science ®Google Scholar
• Lijnen P, Petrov V. Induction of cardiac fibrosis by aldosterone. J Mol Cell Cardiol 2000;32:865–79.
   PubMed Web of Science ®Google Scholar
• Hlubocká Z, Jáchymová M, Heller S, Umnerová V, Danzig VV, Lánská V, et al. Association of the -344T/C aldosterone synthase gene variant with essential hypertension. Physiol Res 2008 Dec 17. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Chua SC, Szabo P, Vitek A, Grzeschik KH, John M, White PC. Cloning of cDNA encoding steroid 11 beta-hydroxylase (P450c11). Proc Natl Acad Sci USA 1987;84:7193–7.
   PubMed Web of Science ®Google Scholar
• Wagner MJ, Ge Y, Siciliano M, Wells DE. A hybrid phatase using a novel monoclonal antibody and peptide elution, cell mapping panel for regional localization of probes to human chromosome 8. Genomics 1991;10:114–25.
   PubMed Web of Science ®Google Scholar
• Mornet E, Dupont J, Vitek A, White PC. Characterizing two genes encoding human steroid 11beta-hydroxylase (P-450(11) beta). J Biol Chem 1989;264:20961–7.
   PubMed Web of Science ®Google Scholar
• Kawamoto T, Mitsuuchi Y, Toda K, Miyahara K, Yokoyama Y, Nakao K, et al. Cloning of cDNA and genomic DNA for human cyto-chrome P-45011beta. FEBS Lett 1990;269:345–9.
   PubMed Web of Science ®Google Scholar
• Mulatero P, Schiavone D, Fallo F, Rabbia F, Veglio F. CYP11B2 gene polymorphisms in idiopathic hyperaldosteronism. Hypertension 2000;35:694–8.
   PubMed Web of Science ®Google Scholar
• Zhu H, Sagnella GA, Dong Y, Miller MA, Onipinla A, Makandu ND, et al. Contrasting associations between aldosterone synthase gene polymorphisms and essential hypertension in blacks and in whites. J Hypertens 2003;21:87–95.
   PubMed Web of Science ®Google Scholar
• White PC, Slutsker L. Haplotype analysis of CYP11B2. Endocr Res 1995;21:437–42.
   PubMed Web of Science ®Google Scholar
• Zucker IH. Novel mechanisms of sympathetic regulation in chronic heart failure. Hypertension 2006;48:1005–11.
   PubMed Web of Science ®Google Scholar
• Yu Y, Wei SG, Zhang ZH, Gomez-Sanchez E, Weiss RM, Felder RB. Does aldosterone upregulate the brain renin-angiotensin system in rats with heart failure? Hypertension 2008;51:727–33.
   PubMed Web of Science ®Google Scholar
• Lindley TE, Doobay MF, Sharma RV, Davisson RL. Superoxide is involved in the central nervous system activation and sympathoexcitation of myocardial infarction-induced heart failure. Circ Res 2004;94:402–9.
   PubMed Web of Science ®Google Scholar
• Huang BS, Ahmad M, Tan J, Leenen FHH. Sympathetic hyperactivity and cardiac dysfunction post-MI: different impact of specific CNS versus general AT1 receptor blockade. J Mol Cell Cardiol 2007;43:479–86.
   PubMed Web of Science ®Google Scholar
• Lal A, Veinot JP, Leenen FHH. Critical role of CNS effects of aldosterone in cardiac remodeling post-myocardial infarction in rats. Cardiovasc Res 2004;64:437–76.
   PubMed Web of Science ®Google Scholar
• Huang BS, Leenen FHH. Blockade of brain mineralocorticoid receptors or Na+ channels prevents sympathetic hyperactivity and improves cardiac function in rats post-MI. Am J Physiol 2005;288:H2491–7.
   Google Scholar
• Huang SB, White AR, Ahmad M, Tan J, Jeng YA, Leenen HHF. Central infusion of aldosterone synthase inhibitor attenuates left ventricular dysfunction and remodeling in rats after myocardial infarction. Cardiovasc Res 2009;81:574–81.
   PubMed Web of Science ®Google Scholar
• MacFadyen RJ, Lee AF, Morton JJ, Pringle SD, Struthers AD. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart 1999;82:57–61.
   PubMed Web of Science ®Google Scholar
• Cicoira M, Zanolla L, Rossi A, Golia G, Franceschini L, Cabrini G, et al. Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype. J Am Coll Cardiol 2001;37:1808–12.
   PubMed Web of Science ®Google Scholar
• Schjoedt KJ, Andersen S, Rossing P, Tarnow L, Parving HH. Aldosterone escape during blockade of the renin–angiotensin–aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 2004;47:1936–9.
   PubMed Web of Science ®Google Scholar
• Naruse M, Tanabe A, Sato A, Takagi S, Tsuchiya K, Imaki T, et al. Aldosterone breakthrough during angiotensin II receptor antagonist therapy in strokeprone spontaneously hypertensive rats. Hypertension 2002;40:28–33.
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709–17.
   PubMed Web of Science ®Google Scholar
• Mantero F, Lucarelli G. Aldosterone antagonists in hypertension and heart failure. Ann Endocrinol (Paris) 2000;61:52–60.
   PubMed Web of Science ®Google Scholar
• Soberman JE, Weber KT. Spironolactone in congestive heart failure. Curr Hypertens Rep 2000;2:451–6.
   PubMedGoogle Scholar
• Delyani JA. Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology. Kidney Int 2000;57:1408–11.
   PubMed Web of Science ®Google Scholar
• Rousseau MF, Gurne O, Duprez D, Van Mieghem W, Robert A, Ahn S, et al. Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy. J Am Coll Cardiol 2002;40:1596–601.
   PubMed Web of Science ®Google Scholar
• Chai W, Garrelds IM, de Vries R, Batenburg WW, van Kats JP, Danser AH. Nongenomic effects of aldosterone in the human heart: interaction with angiotensin II. Hypertension 2005;46:701–6.
   PubMed Web of Science ®Google Scholar
• Fujita M, Minamino T, Asanuma H, Sanada S, Hirata A, Wakeno M, et al. Aldosterone nongenomically worsens ischemia via protein kinase C-dependent pathways in hypoperfused canine hearts. Hypertension 2005; 46:113–17.
   PubMed Web of Science ®Google Scholar
• Varo N, Etayo JC, Zalba G, Beaumont J, Iraburu MJ, Montiel C, et al. Losartan inhibits the post-transcriptional synthesis of collagen type I and reverses left ventricular fibrosis in spontaneously hypertensive rats. J Hypertens 1999;17:107–14.
   PubMed Web of Science ®Google Scholar
• Thai HM, Van HT, Gaballa MA, Goldman S, Raya TE. Effects of AT1 receptor blockade after a myocardial infarct on myocardial fibrosis, stiffness and contractility. Am J Physiol 1999;276:H873–80.
   Google Scholar
• Pilon C, Mulatero P, Barzon L, Veglio F, Garonne C, Boscaro M, et al. Mutations in CYP11B1 gene converting 11beta-hydroxylase into an aldosterone-producing enzyme are not present in aldosterone-producing adenomas. J Clin Endocrinol Metab 1999;84:4228–31.
   PubMed Web of Science ®Google Scholar
• Ulmschneider S, Müller-Vieira U, Mitrenga M, Hartmann RW, Oberwinkler-Marchais S, Klein CD, et al. Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase. J Med Chem 2005;48:1796–805.
   PubMed Web of Science ®Google Scholar
• Ulmschneider S, Müller-Vieira U, Klein CD, Antes I, Lengauer T, Hartmann RW. Synthesis and evaluation of (pyridylmethylene-)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase. J Med Chem 2005;48:1563–75.
   PubMed Web of Science ®Google Scholar
• Heim R, Lucas S, Grombein MC, Ries C, Schewe EK, Negri M, et al. Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on potency and selectivity. J Med Chem 2008;51:5064–74.
   PubMed Web of Science ®Google Scholar
• Lucas S, Heim R, Negri M, Antes I, Ries C, Schewe EK, et al. Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach. J Med Chem 2008;51:6138–49.
   PubMed Web of Science ®Google Scholar
• Voets M, Antes I, Scherer C, Müller-Vieira U, Biemel K, Barassin C, et al. Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis. J Med Chem 2005;48:6632–42.
   PubMed Web of Science ®Google Scholar
• Voets M, Antes I, Scherer C, Müller-Vieira U, Biemel K, Marchais-Oberwinkler S, et al. Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis. J Med Chem 2006;49:2222–31.
   PubMed Web of Science ®Google Scholar
• Lucas S, Heim R, Ries C, Schewe EK, Birk B, Hartmann WR. In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives. J Med Chem 2008;51:8077–87.
   PubMed Web of Science ®Google Scholar
• Pinto-Bazurco Mendieta MA, Negri M, Jagusch C, Müller-Vieira U, Lauterbach T, Hartmann WR. Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer. J Med Chem 2008; 1:5009–18.
   Google Scholar
• Cerius2 version 4.8. San Diego, CA: Accelrys, Inc. (available at: http://www.accelrys.com/cerius2 ).
   Google Scholar
• Leonard JT, Roy K. On selection of training and test sets for the development of predictive QSAR models. QSAR Comb Sci 2006;25:235–51.
   Google Scholar
• Hopfinger AJ, Tokarsi JS. Three-dimensional quantitative structure-activity relationship analysis. In: Charifson PS, ed. Practical Applications of Computer-Aided Drug Design. New York: Marcel Dekker, 1997:105–64.
   Google Scholar
• Fan Y, Shi LM, Kohn KW, Pommier Y, Weinstein JN. Quantitative structure-antitumor activity relationships of camptothecinanalogues: cluster analysis and genetic algorithm-based studies. J Med Chem 2001;44:3254–63.
   PubMed Web of Science ®Google Scholar
• Rogers D, Hopfinger AJ. Application of genetic function approximation to quantitative structure-activity relationship and quantitative structure-property relationship. J Chem Inf Comput Sci 1994;34:854–66.
   Google Scholar
• Dunn WJ III, Rogers D. Genetic partial least squares in QSAR. In: Devillers J, ed. Genetic Algorithms in Molecular Modeling. London: Academic Press, 1996:109–30.
   Google Scholar
• Hasegawa K, Miyashita Y, Funatsu K. GA strategy for variable selection in QSAR studies: GA-based PLS analysis of calcium channel antagonists. J Chem Inf Comput Sci 1997;37:306–10.
   PubMedGoogle Scholar
• Snedecor GW, Cochran WG. Statistical Methods. New Delhi: Oxford & IBH Publishing Co. Pvt. Ltd., 1967.
   Google Scholar
• Wold S, Eriksson L. Statistical validation of QSAR results. Validation tools. In: van de Waterbeemd H, ed. Chemometric Methods in Molecular Design. Weinheim: VCH, 1995:312–17.
   Google Scholar
• Debnath AK. Quantitative structure-activity relationship (QSAR): A versatile tool in drug design. In: Ghose AK, Viswanadhan VN, eds. Combinatorial Library Design and Evaluation. New York: Marcel Dekker, 2001:73–129.
   Google Scholar
• Roy K. On some aspects of validation of predictive QSAR models. Expert Opin Drug Discov 2007;2:1567–77.
   PubMed Web of Science ®Google Scholar
• Roy PP, Roy K. On some aspects of variable selection for partial least squares regression models. QSAR Comb Sci 2008;27:302–13.
   Google Scholar
• Roy K, Roy PP. Comparative QSAR studies of CYP1A2 inhibitor flavonoids using 2D and 3D descriptors. Chem Biol Drug Des 2008;72:370–82.
   PubMed Web of Science ®Google Scholar
• Roy PP, Leonard JT, Roy K. Exploring the impact of the size of training sets for the development of predictive QSAR models. Chemom Intell Lab Syst 2008;90:31–42.
   Web of Science ®Google Scholar
• Eriksson L, Jaworska J, Worth AP, Cronin MTD, McDowell RM, Gramatica P. Methods for reliability and uncertainty assessment and for applicability evaluations of classification- and regression-based QSARs. Environ Health Perspect 2003;111:1361–75.
   PubMed Web of Science ®Google Scholar